Ritter Pharmaceuticals Inc. fell out of compliance with Nasdaq's $1 minimum bid price listing rule.

The Los Angeles-based developer of drugs to treat gastrointestinal diseases has until June 24, 2019, to regain compliance, with a possibility for extension.

The company plans to evaluate available options to address the deficiency and regain compliance with the rule, the company said in a filing.